Mesoblast Ltd Market Cap ($1.98 Billion)
Market Cap & Net Worth: Mesoblast Ltd (MSB)
Mesoblast Ltd market cap. Mesoblast Ltd (AU:MSB) has a market capitalization of $1.98 Billion (AU$2.80 Billion) as of November 4, 2026. Listed on the AU stock exchange, this Australia-based company holds position #5964 globally and #143 in its home market, demonstrating a 21.69% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Mesoblast Ltd's stock price AU$2.16 by its total outstanding shares 1296960871 (1.30 Billion). Also see cash flow conversion of Mesoblast Ltd for how efficiently the company converts equity into cash flow.
Mesoblast Ltd Market Cap History (2015–2026)
Mesoblast Ltd market cap history from 2015 to 2026. Data shows change from $1.59 Billion to $1.98 Billion (-3.62% CAGR). Check Mesoblast Ltd share price for real-time trading data and today's change.
Index Memberships
Mesoblast Ltd is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Australia All Ordinaries
AORD
|
$2.00 Trillion | 0.10% | #123 of 495 |
|
S&P/ASX 300
AXKO
|
$2.15 Trillion | 0.09% | #127 of 300 |
|
ASX Small Ordinaries
AXSO
|
$283.47 Billion | 0.70% | #43 of 200 |
Weight: Mesoblast Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Mesoblast Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Mesoblast Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore how fast is Mesoblast Ltd growing its equity to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
145.14x
Mesoblast Ltd's market cap is 145.14 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $1.23 Billion | $42.55 Million | -$4.13 Million | 28.95x | N/A |
| 2017 | $1.27 Billion | $2.41 Million | -$76.81 Million | 526.68x | N/A |
| 2018 | $1.01 Billion | $17.34 Million | -$35.29 Million | 58.21x | N/A |
| 2019 | $1.81 Billion | $16.72 Million | -$89.80 Million | 108.23x | N/A |
| 2020 | $1.96 Billion | $32.16 Million | -$77.94 Million | 60.88x | N/A |
| 2021 | $1.23 Billion | $7.46 Million | -$98.81 Million | 164.55x | N/A |
| 2022 | $757.00 Million | $10.21 Million | -$91.35 Million | 74.14x | N/A |
| 2023 | $284.48 Million | $7.50 Million | -$81.89 Million | 37.93x | N/A |
| 2024 | $2.84 Billion | $5.90 Million | -$87.96 Million | 482.01x | N/A |
| 2025 | $2.50 Billion | $17.20 Million | -$102.14 Million | 145.14x | N/A |
Competitor Companies of MSB by Market Capitalization
Companies near Mesoblast Ltd in the global market cap rankings as of November 4, 2026. Also see Mesoblast Ltd (MSB) total assets for a full breakdown of the balance sheet.
Key companies related to Mesoblast Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #372 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #411 globally with a market cap of $69.05 Billion USD ( AU$97.59 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #497 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $553.15 |
| #372 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $961.26 |
| #411 | CSL Ltd | AU:CSL | $69.05 Billion | AU$201.16 |
| #497 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $220.83 |
Market Capitalization of Mesoblast Ltd (2015–2026)
Market capitalization of Mesoblast Ltd from 2015 to today. Between 2015 and today, Mesoblast Ltd's market cap moved from $1.59 Billion to $ 1.98 Billion, with a yearly change of -3.62%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | AU$1.98 Billion | -20.59% |
| 2025 | AU$2.50 Billion | -12.26% |
| 2024 | AU$2.84 Billion | +900.00% |
| 2023 | AU$284.48 Million | -62.42% |
| 2022 | AU$757.00 Million | -38.30% |
| 2021 | AU$1.23 Billion | -37.33% |
| 2020 | AU$1.96 Billion | +8.17% |
| 2019 | AU$1.81 Billion | +79.30% |
| 2018 | AU$1.01 Billion | -20.54% |
| 2017 | AU$1.27 Billion | +3.14% |
| 2016 | AU$1.23 Billion | -22.71% |
| 2015 | AU$1.59 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 3rd, 2026 the market cap of Mesoblast Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.98 Billion USD |
| MoneyControl | $1.98 Billion USD |
| MarketWatch | $1.98 Billion USD |
| marketcap.company | $1.98 Billion USD |
| Reuters | $1.98 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Mesoblast Ltd
Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers Remestemcel-L, which is in Phase III clinical trials for the treatment of systemic… Read more